Dr. Jo Van Betsbrugge is a seasoned synthetic organic chemist with over two decades of experience in drug discovery, development, and Chemistry, Manufacturing & Controls (CMC). Jo offers comprehensive CMC support to companies developing small molecule and peptide drugs.
Jo began his career in 1999 as the founder of BioQuadrant Pharmaceutical Intermediates Inc., a chemistry-focused contract development and manufacturing organization (CDMO) specializing in small molecule and peptide drug development. Under his leadership, BioQuadrant successfully executed more than 80 milestone-driven projects for both emerging and established biotech companies. Notably, Jo is a co-inventor and co-developer of Baqsimi™, Eli Lilly’s intranasal dry powder formulation of glucagon, originally developed at BioQuadrant in 2009 for Locemia Solutions (Canada). Baqsimi™ received FDA approval in July 2019.
Jo earned his PhD in organic chemistry from the University of Brussels (Belgium) in 1997 and has received specialized training in cGMP-compliant manufacturing, process validation, and regulatory documentation, including the preparation of CMC sections for NDAs, CTDs, and INDs. He is an active member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).